Skip to main content
African Journal of Urology

Table 1 Demographics of patients stratified by ETD including low and intermediate risk categories who underwent radical prostatectomy

From: Endogenous testosterone density associates with predictors of tumor upgrading and disease progression in the low through favorable intermediate prostate cancer risk categories: analysis of risk factors and clinical implications

 

Population (*)

ETD < 10

ETD > 9,9

P-value

Number

433

219

214

 

Clinical features

Age (years), medians (IQR)

65 (60–70)

65 (61–70)

65 (60–70)

0.53

Body mass index; BMI (kg/m2), medians (IQR)

25.6 (23.7–27.1)

26.1 (24.3–28.1)

25 (23.4–27.1)

 < 0.0001

ET (ng/dL), medians (IQR)

403 (308.3–504.1)

320 (266–400)

482 (406.5–565.9)

 < 0.0001

ETD (ng/(dL x mL)), medians (IQR)

9.9 (6.8–14.8)

6.8 (5.3–8.8)

14.8 (12.4–18.3)

 < 0.0001

PSA (ng/mL), medians (IQR)

5.9 (4.5–7.4)

6.2 (4.7–7.8)

5.5 (4.3–7.0)

0.022

PSAD (ng/(mL x mL)), medians (IQR)

0.14 (0.10–0.20)

0.12 (0.08–0.16)

0.18 (0.12–0.24)

 < 0.0001

PV (mL), medians (IQR)

40 (30–50)

49 (40–60)

30 (24.7–40)

 < 0.0001

BPC (%), medians (IQR)

28.5 (17–45)

27 (14.2–42.0)

30 (20–50)

0.016

BPCD (%/mL), medians (IQR)

0.74 (0.40–1.25)

0.54 (0.31–0.93)

1.00 (0.60–17.3)

 < 0.0001

ASA score, n (%)

ASA 1

46 (10.6)

20 (9.1)

26 (12.1)

0.011

ASA 2

351 (81.3)

173 (79)

179 (83.6)

 

ASA 3

35 (8.1)

26 (11.9)

9 (4.2)

 

Clinical stage, n (%)

   

0.363

cT1c

320 (73.9)

166 (75.8)

154 (72)

 

cT 2a/2b

113 (26.1)

53 (24.2)

60 (28)

 

ISUP, n (%)

   

0.006

ISUP 1

215 (49.7)

123 (56.2)

92 (43)

 

ISUP 2

218 (50.3)

96 (43.8)

122 (57)

 

Pathological features

PW (grams; gr), medians (IQR)

52 (40–65)

60 (50–73)

45 (36.3–55)

 < 0.0001

TL (%), medians (IQR)

15 (10–22)

15 (10–20)

20 (10–25)

0.001

TLD (%/gr), medians (IQR)

0.28 (0.15–0.51)

0.22 (0.12–0.40)

0.38 (0.21–0.66)

 < 0.0001

ISUP, n (%)

   

0.558

ISU p < 3

265 (61.2)

137 (62.6)

128 (59.8)

 

ISUP > 2

168 (38.8)

82 (37.4)

66 (40.2)

 

Pathologic tumor stage, n (%)

0.933

pT2

371 (85.7)

189 (86.3)

182 (85)

 

pT3a

33 (7.6)

16 (7.3)

17 (8.0)

 

pT3b

29 (6.7)

14 (6.4)

15 (7.0)

 

Surgical margins status (SM), n (%)

0.931

negative (NSM)

327 (75.5)

165 (75.3)

162 (75.7)

 

positive (PSM)

106 (24.5)

54 (24.7)

52 (24.3)

 
  1. *Population including European Association of Urology (EAU) low and intermediate risk categories with PSA up to 10 ng/mL, ISUP grade group 1 or 2 and cT1c-2b;
Back to article page